1. Home
  2. SPRO vs VWAV Comparison

SPRO vs VWAV Comparison

Compare SPRO & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.24

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

VWAV

VisionWave Holdings Inc.

HOLD

Current Price

$4.34

Market Cap

139.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
VWAV
Founded
2013
2024
Country
United States
United States
Employees
N/A
12
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
156.3M
139.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
VWAV
Price
$2.24
$4.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.6M
555.0K
Earning Date
05-13-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
N/A
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$300.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.24
N/A
52 Week Low
$1.80
$2.06
52 Week High
$3.08
$15.80

Technical Indicators

Market Signals
Indicator
SPRO
VWAV
Relative Strength Index (RSI) 42.65 39.42
Support Level $2.14 N/A
Resistance Level $2.52 $6.47
Average True Range (ATR) 0.26 0.53
MACD -0.06 -0.09
Stochastic Oscillator 28.64 8.00

Price Performance

Historical Comparison
SPRO
VWAV

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

Share on Social Networks: